<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

Nevro’s Growth Strategies and Challenges in the Spinal Cord Stimulation Market

Posted by Anne Staylor on 5/29/17 3:50 PM

Nevro:  The One to Beat!

In an interview with BioMedGPS, Nevro CEO Rami Elghandour discussed the Company’s success, its growth strategies, and some of the challenges of being the one to beat in the spinal cord stimulation (SCS) market.

nevro logo adjusted.png

Since disrupting the market with its paresthesia-free high frequency (HF10) Senza SCS System, Nevro has set a new standard of care for SCS with unparalleled clinical evidence and success in treating chronic intractable leg and back pain.

Register to download and read now!

The evidence-based Company effectively lit a fire under the SCS market, prompting competitors in this space to develop next generation technologies with an eye toward improving outcomes and overcoming some of the limitations and side effects of standard, tonic SCS. 

 Rami_Headshot.jpg

To find out more about Nevro’s growth strategies, the competitive landscape, and what’s next for the Company, BioMedGPS interviewed Nevro CEO Rami Elghandour via Skype from his office in Redwood City, California.

Read More Now!

 

 

Topics: Neurotherapies

Subscribe to News and Analysis Blog Weekly Emails

SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic and wound care companies. 

Recent Posts